Fonterra probiotics may reduce postnatal depression: study

e0425195-5340-46ce-bce0-92bc53e684e5articleimage.jpg

18 Oct 2017 --- Results of a New Zealand study suggest that Lactobacillus rhamnosus HN001 (DR20) taken during and post-pregnancy positively affected symptoms of maternal depression and anxiety after birth. According to study author Dr. Rebecca Slykerman, the findings are significant as taking a probiotic to assist in postnatal depression is a potentially simple way to help mothers with their mental health.

The study, funded by Fonterra and the Health Research Council, involved 423 women in Auckland and Wellington. In all, 212 women were given the probiotic and 211 a placebo. Mothers in the study who took the probiotic reported significantly lower depression and anxiety scores than those in the placebo group.

“Many women are unable to access psychological therapy or are reluctant to take antidepressant medication in pregnancy or while breastfeeding,” says Dr. Slykerman. “Furthermore, it takes several weeks for the therapeutic effect of antidepressants to appear and there is a 15 to 30 percent discontinuation rate. Safe and effective therapies to prevent and treat postnatal depression are needed.”

Probiotics, which are certain live bacteria and yeasts that can be found in some foods and supplements, are known to provide certain health benefits. Fonterra’s Program Manager for Nutrition and Health Dr. James Dekker indicates that the additional potential benefits from one of its probiotics are encouraging to see.

“It is pleasing to see more evidence of the health benefits of Lactobacillus rhamnosus HN001 (which has been trademarked as DR20 and SureStart LactoB 001), one of our two probiotics,” says Dr. Dekker. “We know not all probiotics are created equal and there needs to be sound evidence for the benefits for each probiotic strain.”

Other recent studies have found that when taken by pregnant women, DR20 may reduce the risk of gestational diabetes as well as reducing the instances of childhood eczema. DR20, along with Fonterra’s other probiotic, Bifidobacterium lactis HN019 (DR10), which helps out with gut health, were patented and commercialized after the screening of more than 2,000 strains in the 1990s.

Currently, DR20 is not commercially available through Fonterra, but it can be found in the Go Healthy “Go derma protect” product sold in pharmacies, while DR10 can be found in the Symbio yogurt range.

Related Articles

Business News

Lakeview Equity invests in nutritional solutions provider NutriScience Innovations

11 Dec 2017 --- Lakeview Equity Partners, LLC, a US$40 million Milwaukee, US-based private equity fund, has invested in NutriScience Innovations, LLC, based in Trumbull, Connecticut, US. NutriScience is a cGMP-certified global supplier of nutritional and functional ingredients to companies that manufacture nutraceutical, pharmaceutical, food and beverage, and dietary products.

Business News

Consuming sugary drinks during pregnancy may increase asthma risk in mid-childhood

08 Dec 2017 --- Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research published online in the Annals of the American Thoracic Society.

Food Ingredients News

NZMP develops innovative fast-digesting milk protein concentrate

08 Dec 2017 --- As part of its ongoing work in the areas of proteins and medical nutrition, Fonterra’s global dairy ingredients B2B brand NZMP has launched a new milk protein concentrate (MPC) coined SureProtein Fast MPC 4868. Compared to standard milk protein offerings, the ingredient is touted as being able to provide muscles with a higher level of amino acids within the first two hours of consumption and is absorbed as quickly as whey protein.

Business News

New Biopolis probiotic mix helps reduce topical steroid use by atopic dermatitis patients

07 Dec 2017 --- Biopolis, majority owned by agricultural processor and food ingredient provider Archer Daniels Midland Company (ADM), has introduced a new probiotic mix designed to reduce the need for topical steroid use by Atopic Dermatitis (AD) patients. The clinical research recently published in JAMA Dermatology, an international peer-reviewed general medical journal, shows the benefits of consuming a mix of probiotics in reducing the need for topical steroids by AD patients.

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

More Articles
URL : http://www.nutritioninsight.com:80/news/fonterra-probiotics-may-reduce-postnatal-depression-study.html